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ABSTRACT
Background: Sentinel lymph node biopsy is widely used in the management of melanoma patients. Multiple markers are
used to stain sentinel lymph node tissue including S100, HMB-45 and melan A with different success. We investigated,
for the first time, the use of Microphthalmia transcription factor (Mitf) staining in a larger series of sentinel lymph
nodes. Mitf is a transcription factor essential for the development and survival of melanocytes. It has been introduced
recently as a sensitive and specific marker for melanomas. Methods: Thirty patients with cutaneous melanoma were
included in our study: twenty patients underwent sentinel lymph node biopsy; ten patients underwent complete lymph
node dissection for clinically positive disease. Results: Ten out of twenty sentinel lymph nodes were negative for tumor
cells and showed no Mitf staining. Out of the ten positive sentinel lymph nodes, eight were also positive for Mitf. Only
four out of the ten clinically positive lymph nodes stained for Mitf. Conclusions: We conclude that Mitf can be used as
an additional marker for evaluating sentinel lymph nodes in patients with melanoma. In addition, our results imply that
Mitf is involved in melanoma differentiation.
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1. Introduction
Trends in the management of patients with malignant
melanoma are rapidly changing. Novel techniques for
lymphatic mapping of regional lymph nodes with sentinel lymphadenectomy have greatly impacted the care of
these patients eliminating the need for elective lymphadenectomy in approximately 80% of cases [1]. Pathogic sentinel lymph node (SLN) status in clinically nodeegative patients is an important independent prognostic
factor [2,3,4]. The number of metastatic nodes, the tumor
burden at the time of staging, and the presence or absence of ulceration of the primary melanoma are the most
significant predictors of outcome as shown in an multivariate analysis of 17,600 melanoma patients [3,4].
However, the presence of melanoma cells in SLNs can
be difficult to detect, even when sections from the entire
node are cut and examined thoroughly. All lymph nodes
other than those that contain obvious tumor on visual
inspection must be examined by immunohistochemistry.
If immunohistochemistry is not routinely performed,
approximately 12% of positive SLNs will be miscategoCopyright © 2011 SciRes.

rized as tumor negative [5]. Traditionally used immunhistochemical markers in melanoma have disadvantages.
Monoclonal antibody to S100 protein, a calcium-binding
protein originally isolated from cow brain, is a sensitive
marker that reacts with more than 90% of melanomas. It
remains the most sensitive marker for both neval cells
and melanomas, including amelanotic and spindle cell
variants, but unfortunately, cannot differentiate benign
from malignant cells [5-8]. In addition, S100 lacks sufficient specificity and reacts with a wide range of tissues
including dentritic cells, Schwann cells, adipocytes,
chondrocytes and others [5-8]. The HMB-45 antibody
recognizes the melanosome-specific glycoprotein gp100
and is specificity is described as high as 97% for detecting melanoma [6]. However, HMB-45 is detectable in
only 50% to 75% of all melanomas [5,6,8]. Melan A
protein is a melanocytic differentiation antigen and a
product of the MART-1 gene. It is a new antibody which
stains both benign and malignant melanocytic lesions in
a very similar fashion to that of S100 and seems to be
more reliable than HMB-45 [8].
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Microphthalmia transcription factor (Mitf) has recently
been introduced as the only nuclear melanocytic marker
[9-11]. Mitf is a transcriptional regulator and a nuclear
component of the signaling transduction pathway [12]. It
is important for the survival of melanocytes and regulates
the expression of several melanocyte genes. Multiple
studies have confirmed that Mitf is a sensitive marker for
epitheloid melanomas: 82% to 100% of melanomas are
positive for Mitf [6,9,10,11,13,14]. Recently we suggested that Mitf may be a new molecular prognostic
marker in melanoma patients with low levels of Mitf
expression correlating with worse prognosis [9]. The use
of Mitf staining in sentinel lymph nodes has only been
investigated in a very small series of four sentinel lymph
nodes up to date [15]. The purpose of the present study
was to further evaluate the usefulness of Mitf staining in
the evaluation of SLNs in patients with melanoma.

2. Patients and Methods
2.1. Patients
We randomly selected 30 patients from the tumor registry of the Department of Surgical Oncology at the University of Illinois in Chicago Medical Center. Twenty
patients with primary melanomas greater that one millimeter thick and clinically negative lymph node basins
underwent sentinel lymph node biopsy following injection of radio labeled colloid and isosulfan blue dye. An
additional ten patients with clinically positive lymph
nodes underwent complete lymph node dissection. All
SLNs and clinically positive nodes were evaluated for
Mitf staining by immunohistochemistry.

2.2. Histopathologic Examination of Lymph
Node Specimens
Standard technique for preparation of SLNs was followed as previously described [16]. Briefly, the excised
lymph nodes were examined in a routine fashion with
visual inspection to detect tumor nodules. The nodes
were bisected from hilum to periphery and then fixed in
10% neutral buffered formalin, embedded in paraffin and
sectioned. The nodal sections were then processed for
routine hematoxylin and eosin (H&E) staining. Lymph
nodes negative for metastasis on H&E staining were also
processed for peroxidase immunostaining using antibodies to HMB-45 or melan-A protein (Dako, Carpinteria,
CA, USA). Both negative and positive control stains
were run simultaneously with the specimens to confirm
the sensitivity and specificity of the immunhistochemical
method. SLNs were level-sectioned for routine H&E
three times, for HMB-45 and melan-A immunohistochemistry two times. All lymph nodes were processed for
Mitf staining: Standard avidin-biotin-peroxidase immuCopyright © 2011 SciRes.
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nohistochemistry was performed with the mouse monoclonal IgG1 micropthalmia antibody D5 (Neomarkers,
Union City, CA, USA). Antigen retrieval was accomplished with 1mM EDTA buffer. We used 1% dried skim
milk to block nonspecific binding before incubation with
the primary antibody for two hours (1:25 dilution). Aminoethylcarbazine was used as a chromagen [9].

3. Results
Of the twenty SLNs, ten had metastatic disease noted by
H&E staining. The remaining ten SLNs did not show
evidence of metastatic disease either by H&E or by immunohistochemistry. All ten negative sentinel lymph
nodes did not express Mitf. Of the positive SLNs eight
(80%) stained for Mitf by immunohistochemistry. These
SLNs were not stained for HMB-45 or Melan A and thus
direct comparison with Mitf staining is not feasible. All
ten clinically-positive lymph nodes showed evidence for
metastatic disease by H&E staining. Only four (40%)
stained positive for Mitf. These results are summarized in
Table 1. Nuclear staining for Mitf is shown in Figure 1.

4. Discussion
Mitf, a bHLHZip (basic/helix-loop-helix/leucine zipper)
transcription factor, is essential for the development and
maintenance of the melanocyte lineage [12,17]. It can
both activate and repress transcription. Several pigment
cell-specific genes, including the tyrosinase (Tyr) and
tyrosinase-related genes, TRP-1 and DCT/TRP-2 are
regulated by Mitf [12,18]. In mice, the allele Mitf mi
leads to complete absence of melanocytes in the homozygous state [12]. In contrast to various melanocytic
markers, such as melanin or c-kit, whose expression may
be lost or difficult to detect in malignant melanocytic
lesions, Mitf expression is usually maintained in human
melanoma specimens [7,9,10,11,13,14]. Different signaling molecules or transcription factors implicated genetically in melanocyte development are known to either
affect Mitf expression or its function [19]. Mitf has
emerged as a potentially important diagnostic marker for
melanoma. King et al reported that Mitf is a sensitive and
specific melanocyte marker for melanoma diagnosis [10].
They showed 100% nuclear staining for 76 primary
melanomas using the monoclonal antibody D5 and in
none of 60 non-melanoma tumors. In a follow-up study
Table 1. Nuclear staining for Mitf.
Lymph node status

Mitf staininga

Negative SLNsb

0

Positive SLNs

8

Clinically-positive lymph nodes

4

a: 10 patients evaluated in each category. b: SLNs = sentinel lymph nodes.
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(a)

(b)

Figure 1. Positive sentinel lymph node of a melanoma patient, original magnification × 10. (a): H&E staining of lymph nodes
showing metastatic melanoma. (b): Note nuclear staining of Mitf (arrow).

the authors demonstrated uniform conservation of Mitf
antibody expression in both benign and malignant melanocytic lesion with the exception of desmoplastic malignant melanomas [7,11].
We previously reported positive Mitf staining in 83%
of patients with intermediate thickness melanomas [9]. In
the years following these initial studies, a multitude of
manuscripts were published describing the utility of Mitf
antibodies for the diagnosis of various types of melanomas and other cancers. Antibody-detected Mitf expression was also found in 100% of benign nevi and 100% of
primary cutaneous melanomas with the exception of
desmoplastic melanomas (1/14) [11]. The literature on
the immunoreactivity of Mitf in melanocytic and non
melanocytic spindle cell lesions remains confusing. Koch
et al reported that 55% (11/20) of spindle cell and desmoplastic melanomas were immunoreactive for Mitf, but
none of 12 malignant peripheral nerve tumors and only 2
of 10 neurofibromas were positive giving Mitf a higher
sensitivity and specificity than that of HMB-45 [20].
Other investigators however were unable to confirm
these findings. In 2 studies, one third to one half of nonmelanocytic spindle cell tumors and only 30% of spindle
cell and desmoplastic melanomas were positive for Mitf
[21,22]. In addition 8% of 386 non-melanocytic tumors
stained positive for Mitf including macrophages, fibroblasts, Schwann cells and smooth muscle cells [22]. On
the other hand the nuclear staining of Mitf can allow for
clearer distinction from pigmented cytoplasm, often a
confounding issue during interpretation [15].
In our study, none of the 10 negative SLNs were upstaged with Mitf staining. In this small number of SLNs,
Mitf demonstrates a specificity of 100%. This is comparable to a specificity of 97% as described by Sheffield et
Copyright © 2011 SciRes.

al. in 72 primary melanomas and 32 nonmelanocytic
malignancies [6] and a specificity of 100% as found by
Dorvault et al. [14]. Miettinen et al. suggest caution in
the use of Mitf in the search for nodal micrometastasis as
they found occasional Mitf-positive nuclei in histiocytes
of germinal centers in 8 out of 20 lymph nodes and in
sinus histiocytes in 7 out of 22 lymph nodes. Interpreting
Mitf-positive histiocytes as melanoma cells should be
avoided [7]. We did not encounter this problem in our 10
negative SLNs. Our study shows that 80% of SLNs
which are positive by H&E staining also stain for Mitf by
immunohistochemistry. In a small serious of only 4 sentinel lymph nodes positive of metastatic melanoma
strong nuclear staining was observed in all 4 lymph
nodes [15]. Interestingly, only 40% of clinically-positive
lymph nodes (all of which show metastatic melanoma by
H&E) stain for Mitf. This is in contrast to the results described by Miettinen et al, who evaluated Mitf staining in
266 metastatic melanomas including 130 patients with
lymph node metastases and found Mitf staining in 88%
of these tumors [7]. It must be noted that in their study,
an antibody cocktail of C5 + D5 was used, whereas we
used pure D5 monoclonal Mitf antibody.
We propose that levels of Mitf expression imply a
more differentiated melanoma and correlate with prognosis. In our previous study we found that mean overall
survival and disease-free survival in patients whose
melanomas did not express Mitf were 80 +/– 18 months
and 71 +/– 20 months respectively. This compared with
187 +/– 13 and 186 +/– 14 months for patients whose
melanomas expressed Mitf [9]. In addition, the pathologic status of the SLN remains the most important
prognostic factor in patients with cutaneous melanoma
[3,23]. The revised melanoma staging system concludes
JCT
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that the number of metastatic lymph nodes and the “tumor burden” were the most dominant predictors of survival in patients with Stage III melanoma [3,4]. Patients
with metastatic nodes detected by palpation had a shorter
survival compared with patients whose nodal metastases
were first detected by sentinel node biopsy. Taken together, the decreased Mitf staining in the macroscopically positive lymph nodes implies that Mitf is a differentiation marker, whose loss of expression correlates
with advanced disease and poor prognosis. In other
words, higher levels of antigen expression represent a
more differentiated state, while lower levels represent a
less differentiated state. Interestingly data supporting this
hypothesis were reported in vitro and in a SCID mice
model by Selzer et al. [24]. The authors nicely demonstrated that transfection of the melanocyte specific isoform of Mitf (Mitf-M) into a melanoma cell line (518A2)
lacking the M-isoform and into a permanent cell line
established from normal melanocytes (NMEL-II) resulted in slower tumor growth. In addition to the growthinhibitory effects, Mitf-M expression led to a change in
the histopathological appearance of tumors from epitheloid toward a spindle-cell type in vivo. Similarly, we
have shown that Mitf-M transfected into the aggressive
UISO-Mel-6 melanoma cell lines abrogated liver and
lung metastases and upregulated the markers of differentiation [25].
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5. Conclusions
Our results show that Mitf can be used as an additional
marker for evaluating sentinel lymph nodes in patients
with melanoma. To confirm these preliminary results in a
relative small number of patients, larger studies will be
necessary. In addition, Mitf appears to be involved in
melanoma differentiation and leads to a less aggressive
phenotype.
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